NCT00431041View on ClinicalTrials.gov

Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)

PHASE4CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Overactive Bladder
Interventions
DRUG

solifenacin

Oral

DRUG

oxybutynin immediate release

Oral

Trial Locations (12)

T2V 4R6

Calgary

T5H 3V9

Edmonton

V6T 2B5

Vancouver

V8T 5G1

Victoria

B3H 3A7

Halifax

N1H 5J1

Guelph

N2N 2B9

Kitchener

M4N 3M5

Toronto

M5G 1Z5

Toronto

M5T 2S8

Toronto

M6A 3B5

Toronto

H3T 1E2

Montreal

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma Canada, Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY

NCT00431041 - Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) | Biotech Hunter | Biotech Hunter